10.1002/chem.202001123
Chemistry - A European Journal
RESEARCH ARTICLE
(Eds.: N. J. Westwood, A. Nelson), The Royal Society Of Chemistry,
2018, pp. 74–113.
Acknowledgements
[17] a) N. Palmer, T. M. Peakman, D. Norton, D. C. Rees, Org. Biomol. Chem.
2016, 14, 1599–1610; b) H. Prevet, M. Flipo, P. Roussel, B. Deprez, N.
Willand, Tetrahedron Lett. 2016, 57, 2888–2894; c) N. C. Tran, H.
Dhondt, M. Flipo, B. Deprez, N. Willand, Tetrahedron Lett. 2015, 56,
4119–4123; d) K. F. Morgan, I. A. Hollingsworth, J. A. Bull, Chem.
Commun. 2014, 50, 5203–5205; e) S. J. Chawner, M. J. Cases-Thomas,
J. A. Bull, Eur. J. Org. Chem. 2017, 2017, 5015–5024; f) A. J. Boddy, D.
P. Affron, C. J. Cordier, E. L. Rivers, A. C. Spivey, J. A. Bull, Angew.
Chem. Int. Ed. 2019, 58, 1458-1462; Angew. Chem. 2019, 131 ,1472–
1476; f) P. Garner, P. B. Cox, U. Rathnayake, N. Holloran, P. Erdman,
ACS Med. Chem. Lett. 2019, 10, 811–815; g) R. Zhang, P. J. McIntyre,
P. M. Collins, D. J. Foley, C. Arter, F. von Delft, R. Bayliss, S. Warriner,
A. Nelson, Chem. – A Eur. J. 2019, 25, 6831–6839; h) A. Sveiczer, A. J.
P. North, N. Mateu, S. L. Kidd, H. F. Sore, D. R. Spring, Org. Lett. 2019,
21, 4600; i) D. G. Twigg, N. Kondo, S. L. Mitchell, W. R. J. D. Galloway,
H. F. Sore, A. Madin, D. R. Spring, Angew. Chem. Int. Ed. 2016, 55,
12479-12483; Angew. Chem. 2016, 128 ,12667-12671; j) T. A. King, H.
L. Stewart, K. T. Mortensen, A. J. P. North, H. F. Sore, D. R. Spring, Eur.
J. Org. Chem. 2019, 2019, 5219–5229; k) A. R. Hanby, N. S. Troelsen,
T. J. Osberger, S. L. Kidd, K. T. Mortensen, D. R. Spring, Chem.
Commun. 2020, 56, 2280–2283.
We are grateful to AstraZeneca, Astex Pharmaceuticals, Lilly,
Pfizer and Vernalis for supporting this venture. This project was
funded by the EPSRC (MCW), BBSRC (BB/N008332/1) (JDF),
University of York (TDD, SPJ), Asahi Kasei (MA), the EU (Horizon
2020 program, Marie Skłodowska-Curie grant agreement No.
675899, FRAGNET) (HFK) and the Wellcome Trust
(Infrastructure Award to C2D2 for the York Chemical Biology
Facility, PSB). We thank Natalie Charlesworth and Scott
Grossman for preliminary synthetic work, Biovia for supplying
Pipeline Pilot software and Dr Adrian C Whitwood and Rachel
Bean for X-ray crystallography.
Keywords: conformational diversity • 3-D fragments • fragment-
based drug discovery • medicinal chemistry • synthesis design
[1]
a) C. W. Murray, D. C. Rees, Nat. Chem. 2009, 1, 187–192; b) R. E.
Hubbard, J. B. Murray, Methods Enzymol. 2011, 493, 509–531; c) M.
Congreve, G. Chessari, D. Tisi, A. J. Woodhead, J. Med. Chem. 2008,
51, 3661–3680; d) G. M. Keserű, D. A. Erlanson, G. G. Ferenczy, M. M.
Hann, C. W. Murray, S. D. Pickett, J. Med. Chem. 2016, 59, 8189–8206;
e) B. Lamoree, R. E. Hubbard, Essays Biochem. 2017, 61, 453-464.
G. Bollag, J. Tsai, J. Zhang, C. Zhang, P. Ibrahim, K. Nolop, P. Hirth, Nat.
Rev. Drug Discov. 2012, 11, 873–886.
[18] a) S. Haftchenary, S. D. Nelson Jr., L. Furst, S. Dandapani, S. J. Ferrara,
Ž. V. Bošković, S. F. Lazú, A. M. Guerrero, J. C. Serrano, D. K. Crews,
C. Brackeen, J. Mowat, T. Brumby, M. Bauser, S. L. Schreiber, A. J.
Phillips, ACS Comb. Sci. 2016, 18, 569–574; b) H. Hassan, S. P.
Marsden, A. Nelson, Bioorg. Med. Chem. 2018, 26, 3030–3033; c) N.
Mateu, S. L. Kidd, L. Kalash, H. F. Sore, A. Madin, A. Bender, D. R.
Spring, Chem. – A Eur. J. 2018, 24, 13681–13687; d) Y. Wang, J.-Y.
Wach, P. Sheehan, C. Zhong, C. Zhan, R. Harris, S. C. Almo, J. Bishop,
S. J. Haggarty, A. Ramek, K. N. Berry, C. O'Herin, A. N. Koehler, A. W.
Hung, D. W. Young, ACS Med. Chem. Lett. 2016, 7, 852–856.
[19] H. Prescher, G. Koch, T. Schuhmann, P. Ertl, A. Bussenault, M. Glick, I.
Dix, F. Petersen, D. E. Lizos, Bioorg. Med. Chem. 2017, 25, 921–925.
[20] N. S. Troelsen, E. Shanina, D. Gonzalez-Romero, D. Dankova, I. S. A.
Jensen, K. J. Sniady, F. Nami, H. Zhang, C. Rademacher, A. Cuenda, C.
H. Gotfredsen, M. H. Clausen, Angew. Chem. Int. Ed. 2020, 59, 2204-
2210; Angew. Chem. 2020, 132 ,2224-2230.
[2]
[3]
A. J. Souers, J. D. Leverson ,E. R. Boghaert, S. L. Ackler ,N. D. Catron,
J. Chen, B. D. Dayton, H. Ding ,S. H. Enschede ,W. J. Fairbrother, D. C.
Huang ,S. G. Hymowitz, S. Jin, S. L. Khaw, P. J. Kovar, L. T. Lam, J. Lee,
H. L. Maecker, K. C. Marsh, K. D. Mason, M. J. Mitten, P. M. Nimmer, A.
Oleksijew, C. H. Park, C. M. Park, D. C. Phillips, A. W. Roberts, D.
Sampath, J. F. Seymour, M. L. Smith, G. M. Sullivan, S. K. Tahir, C. Tse,
M. D. Wendt, Y. Xiao, J. C. Xue, H. Zhang, R. A. Humerickhouse, S. H.
Rosenberg, S. W. Elmore, Nat. Med. 2013, 19, 202–208.
[4]
a) T. P. S. Perera, E. Jovcheva, L. Mevellec, J. Vialard, D. De Lange, T.
Verhulst, C. Paulussen, K. Van De Ven, P. King, E. Freyne, D. C. Rees,
M. Squires, G. Saxty, M. Page, C. W. Murray, R. Gilissen, G. Ward, N.
T. Thompson, D. R. Newell, N. Cheng, L. Xie, J. Yang, S. J. Platero, J.
D. Karkera, C. Moy, P. Angibaud, S. Laquerre and M. V. Lorenzi Mol.
Cancer Ther. 2017, 16, 1010-1020 ; b) C. W. Murray, D. R. Newell, P.
Angibaud, Med. Chem. Commun. 2019, 10, 1509-1511.
[21] T. J. Ritchie, S. J. F. Macdonald, Drug Discov. Today 2009, 14, 1011–
1020.
[22] N. C. Firth, N. Brown, J. Blagg, J. Chem. Inf. Model. 2012, 52, 2516–
2525.
[5]
[6]
[7]
[8]
D. A. Erlanson, S. W. Fesik, R. E. Hubbard, W. Jahnke, H. Jhoti, Nat.
Rev. Drug Discov. 2016, 15, 605–619.
[23] W. H. B. Sauer, M. K. Schwarz, J. Chem. Inf. Comput. Sci. 2003, 43,
987–1003.
M. Congreve, R. Carr, C. Murray, H. Jhoti, Drug Discov. Today 2003, 8,
876–877.
[24] E. Vitaku, D. T. Smith, J. T. Njardarson, J. Med. Chem. 2014, 57, 10257–
10274.
R. J. Hall, P. N. Mortenson, C. W. Murray, Prog. Biophys. Mol. Biol. 2014,
116, 82–91.
[25] Racemic compounds are preferred due to synthetic efficiency and
increased hit rates during screening.
A. D. Morley, A. Pugliese, K. Birchall, J. Bower, P. Brennan, N. Brown,
T. Chapman, M. Drysdale, I. H. Gilbert, S. Hoelder, , A. Jordan, S. V. Ley,
A. Merritt, D. Miller, M. E. Swarbrick, P. G. Wyatt, Drug Discov. Today
2013, 18, 1221–1227.
[26] For examples of Fig. 1A, 1B, 1C and 3A in which the positions are
indicated with reference to their Boltzmann populations, see the SI.
[27] F. Kelleher, S. Kelly, J. Watts, V. McVee Tetrahedron 2010, 66, 3525.
[28] For reviews of pyridine hydrogenation see: a) M. G. P. Buffat,
Tetrahedron 2004, 60, 1701–1729; b) M. Balasubramanian, in Pyridines:
From Lab to Production (Eds.: E. F. V. Scriven), Academic Press, Oxford,
2013, pp. 413–458.
[9]
A. W. Hung, A. Ramek, Y. Wang, T. Kaya, J. A. Wilson, P. A. Clemons,
D. W. Young, Proc. Natl. Acad. Sci. 2011, 108, 6799–6804.
[10] B. Over, S. Wetzel, C. Grütter, Y. Nakai, S. Renner, D. Rauh, H.
Waldmann, Nat. Chem. 2013, 5, 21–28.
[29] This unexpected trans-diastereoselectivity is precedented, see: M. Irfan,
E. Petricci, T. N. Glasnov, M. Taddei, C. O. Kappe, Eur. J. Org. Chem.
2009, 2009, 1327–1334.
[11] N. Fuller, L. Spadola, S. Cowen, J. Patel, H. Schönherr, Q. Cao, A.
McKenzie, F. Edfeldt, A. Rabow, R. Goodnow, Drug Discov. Today 2016,
21, 1272–1283.
[30] C. Cox, B. Flores, J. Schreier, (Merck), WO2010/048016.
[31] S. Ayesa, O. Belda, C. Bjorklund, M. Nilsson, F. Russo, C. Sahlberg, D.
Wiktelius, (Medivir AB), WO2013/095275, 2013.
[12] S. L. Kidd, T. J. Osberger, N. Mateu, H. F. Sore, D. R. Spring, Front.
Chem. 2018, 6, 460.
[13] M. M. Hann, A. R. Leach, G. Harper, J. Chem. Inf. Comput. Sci. 2001,
41, 856–864.
[32] The use of a tert-butyl ester was crucial to obtain the pyrrolidine as a
single diastereomer.
[14] F. Lovering, J. Bikker, C. Humblet, J. Med. Chem. 2009, 52, 6752–6756.
[15] F. Lovering, Med. Chem. Commun. 2013, 4, 515–519.
[16] For a recent review see: J. D. Firth, P. O’Brien, in Chemical and
Biological Synthesis: Enabling Approaches for Understanding Biology
[33] E. Coudert, F. Acher, R. Azerad, Synthesis 1997, 863–865.
[34] D. Solé, X. Urbaneja, J. Bonjoch, Adv. Synth. Catal. 2004, 346, 1646–
1650.
6
This article is protected by copyright. All rights reserved.